Elanco Animal Health (NYSE:ELAN) Stock Price Down 4.6%

Elanco Animal Health Incorporated (NYSE:ELAN) was down 4.6% on Friday . The company traded as low as $12.94 and last traded at $12.94. Approximately 1,947,957 shares changed hands during trading, a decline of 55% from the average daily volume of 4,348,066 shares. The stock had previously closed at $13.57.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ELAN shares. Barclays increased their price target on shares of Elanco Animal Health from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Stifel Nicolaus upgraded Elanco Animal Health from a “hold” rating to a “buy” rating and increased their price objective for the company from $13.00 to $20.00 in a research note on Friday, January 5th. TheStreet raised Elanco Animal Health from a “d+” rating to a “c-” rating in a research note on Friday, February 23rd. The Goldman Sachs Group increased their price target on Elanco Animal Health from $12.50 to $14.00 and gave the company a “sell” rating in a research report on Tuesday, February 27th. Finally, Morgan Stanley lifted their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.71.

Elanco Animal Health Stock Down 5.9 %

The company has a quick ratio of 1.35, a current ratio of 2.75 and a debt-to-equity ratio of 0.92. The business’s fifty day moving average price is $15.72 and its 200 day moving average price is $13.64. The firm has a market capitalization of $6.30 billion, a PE ratio of -5.15, a PEG ratio of 1.41 and a beta of 1.29.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.02). The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1 billion. Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.19 earnings per share. On average, equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Insider Transactions at Elanco Animal Health

In other news, Director R David Hoover purchased 20,000 shares of the company’s stock in a transaction dated Wednesday, March 6th. The stock was acquired at an average price of $16.14 per share, for a total transaction of $322,800.00. Following the completion of the transaction, the director now directly owns 185,000 shares in the company, valued at approximately $2,985,900. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 6.40% of the company’s stock.

Institutional Trading of Elanco Animal Health

Several hedge funds and other institutional investors have recently bought and sold shares of ELAN. Jones Financial Companies Lllp purchased a new stake in Elanco Animal Health in the fourth quarter valued at approximately $37,000. Groupama Asset Managment acquired a new position in shares of Elanco Animal Health in the 4th quarter valued at $40,000. Comerica Bank purchased a new stake in shares of Elanco Animal Health during the 3rd quarter valued at $40,000. Advisory Services Network LLC increased its holdings in shares of Elanco Animal Health by 104.1% during the 1st quarter. Advisory Services Network LLC now owns 5,204 shares of the company’s stock worth $49,000 after buying an additional 2,654 shares during the last quarter. Finally, Captrust Financial Advisors raised its position in shares of Elanco Animal Health by 57.0% in the 1st quarter. Captrust Financial Advisors now owns 2,690 shares of the company’s stock worth $70,000 after buying an additional 977 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.